Schering-Plough Licensing Toyama Antibiotic Garenoxacin, Picking Up Where Bristol Left Off

In-licensing of the quinolone will help fill Schering’s pipeline gap and build its anti-infectives portfolio. Toyama previously licensed the drug to Bristol, which returned rights five months ago. NDA submission will be based on completed Phase III studies in respiratory, skin and skin structure, and abdominal infections.